Autopsy report · NCT03162562

The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer

“Sponsor Decision to discontinue long-term follow-up”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 3 years 5 months before it stopped.
• 10 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

CanariaBio Inc.

Sponsor type

Industry

Conditions

Cancer of Ovary; Neoplasms, Ovarian; Ovarian Cancer Stage IV; Ovarian Cancer Recurrent; Ovarian Cancer Stage III; Ovary Cancer

Interventions

Oregovomab; Poly ICLC

Participants

10

Sites

2

Countries

United States

Trials that died the same way

• A Post-Market Clinical Evaluation of the ReUnion Reverse Shoulder Arthroplasty (RSA) System
  “Sponsor decision to stop at 2 year follow-up” (87% match in meaning)
• Consolidation Therapy in Patients With Metastatic Solid Malignancies
  “Sponsor decision to discontinue study.” (78% match in meaning)
• Yttrium-90 Radioembolization + Nivolumab for Liver + Extra-hepatic Metastases From Colorectal Cancer
  “Sponsor chose not to continue” (76% match in meaning)
• SURF, Neurodevelopment, Growth Study in SGA Infants
  “Sponsor decision stopped in June 2017” (75% match in meaning)
• ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases
  “Terminated - Sponsor Decision” (74% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.